Fig. 1From: Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinomaa Progression-free survival (N = 72) and b overall survival (N = 74) of patients in the anti-PD-1/TA + SBRT group and the anti-PD-1/TA alone groupBack to article page